Healthcare Industry News: radiotherapy
News Release - November 4, 2015
ZEISS Introduces OPMI PENTERO 800 to Reconstructive SurgeryJENA, Germany, November 4, 2015 -- (Healthcare Sales & Marketing Network) -- ZEISS is now adding INFRARED 800 to its OPMIŽ PENTEROŽ 800 surgical microscope for reconstructive surgery. The new enhancements are tailored to the requirements of breast reconstruction, lymph supermicrosurgery, and oral and maxillofacial surgery. Clinical specialists can benefit from the optimized package of ZEISS OPMI PENTERO 800 which provides intraoperative assessment of blood flow, higher magnification and effortless maneuverability required for complex reconstructive surgery.
Optimal image quality, visualization of blood flow and good maneuverability of the microscope are particularly important for surgeons during demanding surgical procedures on delicate structures. Since the introduction of its premium-class OPMI Pentero surgical microscope from ZEISS in 2004, ZEISS has worked on ensuring the utility and availability of its products for a wider range of clinical applications. OPMI PENTERO 800 with INFRARED 800 is tailored to the needs of reconstructive surgeons, especially for breast reconstruction procedures, lymphedema supermicrosurgery as well as oral and maxillofacial surgery.
"We are pleased to present the visualization solution that addresses the specific challenges posed by the demanding field of reconstructive surgery," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "OPMI PENTERO 800 with INFRARED 800 is designed to assist and support clinicians during the crucial phase of intraoperative decision-making."
OPMI PENTERO 800 in combination with INFRARED 800 offers an optimized optical package featuring effortless maneuverability which aids reconstructive surgeons during complex clinical procedures:
- INFRARED 800 for OPMI PENTERO 800 enables intraoperative* visual assessment of blood flow and vessel patency, complementing the precision optics of the OPMI PENTERO 800 surgical microscope. INFRARED 800 fluorescence technology allows the capture and recording of fluorescent light, which is invisible to the human eye, and therefore provides surgeons with additional information on blood flow dynamics during surgical interventions. INFRARED 800 is fully integrated into the surgical microscope and can be easily activated by the simple press of a button.
- Surgery on delicate sub-millimeter anatomical structures requires appropriate magnification levels. OPMI PENTERO 800 offers higher magnification levels of up to 39x
- The full-integration concept ensures complete flexibility and ease of use by avoiding any external attachments to the microscope´s head
- The free-floating movement of the OPMI PENTERO 800 and INFRARED 800 system allows clinicians greater maneuverability and flexible positioning of the microscope head during the surgical procedure. Additionally, an intuitive XY function, which supports fine positioning, helps to comfortably visualize the anatomy even while working long hours.
- Further workflow efficiency and comfort for the clinicians is provided by AutoDrapeŽ, AutoBalance[TM] and AutoFokus[TM] which allow for rapid OR setup, fast balancing and automatic sharp focus on the region of interest without any time-consuming manual adjustments.
*Please use the fluorescent agent as per the approval status for the application in your country
Press contact: Jann Gerrit Ohlendorf, Group Communications, Carl Zeiss Meditec AG, Phone +49(0)3641-220-331, Email: email@example.com
Contact for investors: Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG, Phone +49(0)3641-220-116, Email: firstname.lastname@example.org
Carl Zeiss Meditec AG (ISIN:DE0005313704), which is listed on TecDax of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2013/14 (ended 30 September) the company's around 3,000 employees generated revenue of EUR 909 million.
Carl Zeiss Meditec headquarters are located in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the company's presence in these fast-growing countries. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65% are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.
Source: Carl Zeiss Meditec
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.